Back to search

Sweden· SE-20250718000029

Tafamidis STADA Nordic 61 mg Kapsel, mjuk

A tafamidis product containing tafamidis, registered in Sweden by STADA Nordic ApS. The same ATC class is registered in 17 of our 19 countries.

ATC N07XX08

Checked against Swedish Medical Products Agency (Sweden) on

Informational only — not a medical device.

SOURCE REGISTER · SESwedish Medical Products Agency (Sweden)normalisedTafamidis STADA Nordic 61 mg Kapsel, …ATCN07XX08REGISTER NO.SE-20250718000029PACKS LISTED1CHECKEDOctober 1, 2026

Where it is registered

Tafamidis is registered in 17 of 19 countries.

Countries holding a registration under ATC N07XX08 (tafamidis), each read from that country’s own register.

  • This record: Sweden, from Swedish Medical Products Agency (Sweden)
  • 9 of them publish a price we can compare per daily dose

Tafamidis · ATC N07XX08

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tafamidis costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.082 in France to $118.78 in Switzerland — a ×1457 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Tafamidis · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$118.78
  • FR France$0.082
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swedish Medical Products Agency (Sweden)
Active substance
Tafamidis
Manufacturer
STADA Nordic ApS
Country
Sweden (SE)
ATC code
N07XX08
ATC class
Tafamidis
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
Swedish Medical Products Agency (Sweden)
Last checked
October 1, 2026

Packs & prices · 1

  • se_varunummer
    20250718000029

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

18 interactions on record for tafamidis.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tafamidis · interactions on record

18 records

  • 2 severe
  • 16 moderate

Most severe, free to view

  • OzanimodL04AA38severe
  • OzanimodL04AE02severe
  • EltrombopagB02BX05moderate
  • LusutrombopagB02BX07moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tafamidis in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tafamidis products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Austria · Tafamidis Stada, Tafamidis Viatris
  • Belgium · Tafamidis Viatris
  • Germany · Tafamidis Al, Tafamidis Viatris
  • Spain · Tafamidis Stada, Tafamidis Viatris
  • France · Tafamidis Biogaran, Tafamidis Eg
  • United Kingdom (Northern Ireland) · Tafamidis Thornton & Ross
  • Iceland · Vyndaqel
  • Liechtenstein · Vyndaqel
  • Norway · Tafamidis Stada Nordic, Tafamidis Viatris
  • Slovenia · Tafamidis Sumar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6bf25efb-d3a0-42d7-9387-c891dd1822c1
GET /v1/drugs/6bf25efb-d3a0-42d7-9387-c891dd1822c1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "lakemedelsverket",
  "doc_types": [
    "SmPC",
    "PL"
  ],
  "se_npl_id": "20250718000029",
  "product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20250718000029",
  "product_doc_link": "https://docetp.mpa.se/LMF/Tafamidis%20STADA%20Nordic%20capsule%2C%20soft%20SmPC_09001bee8518ab23.pdf"
}

See everything about tafamidis.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.